JP2006517970A5 - - Google Patents

Download PDF

Info

Publication number
JP2006517970A5
JP2006517970A5 JP2006503521A JP2006503521A JP2006517970A5 JP 2006517970 A5 JP2006517970 A5 JP 2006517970A5 JP 2006503521 A JP2006503521 A JP 2006503521A JP 2006503521 A JP2006503521 A JP 2006503521A JP 2006517970 A5 JP2006517970 A5 JP 2006517970A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
cancer
cancer therapeutic
antibody
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006503521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/004116 external-priority patent/WO2004074437A2/en
Publication of JP2006517970A publication Critical patent/JP2006517970A/ja
Publication of JP2006517970A5 publication Critical patent/JP2006517970A5/ja
Pending legal-status Critical Current

Links

JP2006503521A 2003-02-14 2004-02-13 癌免疫療法のための組成物及び方法 Pending JP2006517970A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44771403P 2003-02-14 2003-02-14
PCT/US2004/004116 WO2004074437A2 (en) 2003-02-14 2004-02-13 Compositions and methods for cancer immunotherapy

Publications (2)

Publication Number Publication Date
JP2006517970A JP2006517970A (ja) 2006-08-03
JP2006517970A5 true JP2006517970A5 (https=) 2007-04-05

Family

ID=32908487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503521A Pending JP2006517970A (ja) 2003-02-14 2004-02-13 癌免疫療法のための組成物及び方法

Country Status (5)

Country Link
US (3) US8795672B2 (https=)
EP (1) EP1599572A4 (https=)
JP (1) JP2006517970A (https=)
CA (1) CA2516028C (https=)
WO (1) WO2004074437A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517970A (ja) * 2003-02-14 2006-08-03 ユニバーシティ オブ サザン カリフォルニア 癌免疫療法のための組成物及び方法
CA2585776A1 (en) * 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
GB0525535D0 (en) * 2005-12-15 2006-01-25 Cgt Corp Tumour treatment
US20090317407A1 (en) * 2006-05-02 2009-12-24 Lacelle Michael G Augmentation of immune response to cancer vaccine
AU2007271398B2 (en) * 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
US8536310B2 (en) * 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
WO2009114110A1 (en) * 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
US11071754B2 (en) * 2013-03-11 2021-07-27 Case Western Reserve University Method of generating tumor-specific T cells
US9944992B2 (en) 2013-03-15 2018-04-17 The University Of Chicago Methods and compositions related to T-cell activity
EP3057662A4 (en) * 2013-10-17 2017-03-29 Children's Hospital Los Angeles Antibody dependent exosome therapy
MX387323B (es) * 2014-02-19 2025-03-18 Merck Patent Gmbh Il-12 dirigida al cáncer en combinación con il-7 para usarse en el tratamiento de cáncer.
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
CN109415431A (zh) 2016-04-20 2019-03-01 爱兰细胞技术公司 与k180二甲基化h1.0蛋白相关的组合物和方法
CA3044424C (en) 2016-11-21 2023-05-23 Nant Holdings Ip, Llc Fractal combination therapy
KR102698752B1 (ko) * 2017-03-20 2024-08-26 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
CN111770761B (zh) 2017-10-25 2024-07-09 爱兰细胞技术公司 H1.0k180me2抗体、其制造方法和用途
US10752691B2 (en) 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
US20220112257A1 (en) * 2019-01-11 2022-04-14 Arbele Limited Mul tispecific prochemokine therapeutic proteins (park) and method of making and using thereof
JP2023525060A (ja) 2020-05-14 2023-06-14 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｄ２５抗体、その抗原結合断片及びその医薬用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
DK0527798T3 (da) 1990-04-06 1997-12-15 Jolla Cancer Res Found Fremgangsmåde og sammensætning til behandling af thrombose
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69523857T2 (de) * 1994-09-16 2002-06-13 Merck Patent Gmbh Immunokonjugate
US5767071A (en) 1995-06-07 1998-06-16 Ixsys Incorporated Sevenmer cyclic peptide inhibitors of diseases involving αv β3
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
GB9814383D0 (en) 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
US6365619B1 (en) 1999-07-22 2002-04-02 Novartis Ag Treatment of arteriosclerosis
US6356619B1 (en) * 2000-06-02 2002-03-12 General Electric Company Varying x-ray tube focal spot dimensions to normalize impact temperature
JP2004520043A (ja) * 2001-01-24 2004-07-08 シェーリング　コーポレイション 免疫応答のアジュバントとしてのケモカイン
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
JP2006517970A (ja) 2003-02-14 2006-08-03 ユニバーシティ オブ サザン カリフォルニア 癌免疫療法のための組成物及び方法

Similar Documents

Publication Publication Date Title
JP2006517970A5 (https=)
Yin et al. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
DeVita et al. The chemotherapy of lymphomas: looking back, moving forward—the Richard and Hinda Rosenthal Foundation award lecture
Valent et al. Immunotherapy-based targeting and elimination of leukemic stem cells in AML and CML
EP3057991B1 (en) Chimeric antigen receptor t cell switches and uses thereof
Wu et al. Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy
ES2981745T3 (es) Agentes de señalización biespecíficos y usos de los mismos
Uricoli et al. Engineered cytokines for cancer and autoimmune disease immunotherapy
Mack et al. The next generation of antibody drug conjugates
KR20230147740A (ko) Pd-1/pd-l1 억제제
JP2016509582A5 (https=)
WO2016154621A1 (en) SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
JP2017507936A5 (https=)
CA2516028A1 (en) Conjugates comprising a cancer targeting molecule linked to a liver-expressed chemokine
Quiles et al. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy
WO2006050172A3 (en) Combination cancer immunotherapy with co-stimulatory molecules
RU2017144606A (ru) Иммуноцитокины на основе il-15 и il-15rа домена sushi
JP2018510132A5 (https=)
JP2025072462A (ja) 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化
JP2012102122A5 (https=)
AR042977A1 (es) Formulaciones farmaceuticas liquidas de palonosetron
KR20160022370A (ko) 면역요법을 위한 조성물 및 방법
CN111971060A (zh) 募集抗体并靶向肿瘤细胞的双功能分子
JP2025527534A (ja) 抗－ヒト表皮成長因子受容体２（ｈｅｒ２）キメラ抗原受容体（ｃａｒ）を含むナチュラルキラー細胞を投与する方法
JP2009510165A5 (https=)